

1 **Title Page**

2 **Intraocular pressure, primary open-angle glaucoma and the risk of retinal vein occlusion:**  
3 **a Mendelian randomization mediation analysis**

4 **Authors:** Andreas Katsimpris <sup>1</sup>, Sebastian-Edgar Baumeister <sup>2</sup>, Nafsika Voulgari <sup>1</sup>, Hansjörg  
5 Baurecht <sup>3</sup>, Stylianos Kandarakis <sup>4</sup>, Michael Nolde <sup>2</sup>

6

7

8

9 **Affiliations**

- 10 1. Princess Alexandra Eye Pavilion, University of Edinburgh, Edinburgh, UK  
11 2. Institute of Health Services Research in Dentistry, University of Münster, Münster,  
12 Germany  
13 3. Department of Epidemiology and Preventive Medicine, University of Regensburg,  
14 Regensburg, Germany  
15 4. First Department of Ophthalmology, National and Kapodistrian University of Athens,  
16 Athens, Greece

17 **Corresponding authors**

18 Andreas Katsimpris, Department of Ophthalmology, Princess Alexandra Eye Pavilion, University  
19 of Edinburgh, Edinburgh, EH3 9HA, UK, email: [a.katsimpris@gna-gennimatas.gr](mailto:a.katsimpris@gna-gennimatas.gr), telephone:  
20 +447311299859, ORCID ID: <https://orcid.org/0000-0002-5805-105X>

21 Michael Nolde, Institute of Health Services Research in Dentistry, University of Münster,  
22 Germany, email: [nolde@uni-muenster.de](mailto:nolde@uni-muenster.de), ORCID ID: <https://orcid.org/0000-0001-6893-7367>

23 **Abstract**

24 **Background:** The etiological connection between intraocular pressure (IOP) and the risk of  
25 retinal vein occlusion (RVO) remains elusive, particularly regarding whether this risk emanates  
26 from the direct influence of elevated intraocular pressure (IOP), irrespective of the presence of  
27 primary open-angle glaucoma (POAG), or if it arises as a consequence of the sequelae of  
28 POAG. Therefore, we conducted a Mendelian Randomization (MR) mediation analysis to  
29 elucidate the mediating role of POAG in the association between IOP and RVO.

30 **Methods:** We identified 47 single-nucleotide polymorphisms (SNPs) associated with IOP (P-  
31 value  $< 5 \times 10^{-8}$ ) leveraging data from a genome-wide association study (GWAS) (N = 97,653)  
32 obtained from the UK Biobank and 50 SNPs associated with POAG (P-value  $< 5 \times 10^{-8}$ ) from a  
33 GWAS meta-analysis (16,677 cases and 199,580 controls). We related these SNPs with RVO  
34 using a GWAS of 775 RVO cases and 376,502 controls from FinnGen. By utilizing univariable  
35 and multivariable MR analyses we calculated the total effect of IOP on RVO and estimated the  
36 degree to which POAG mediates this association.

37 **Results:** MR analyses showed that higher IOP is associated with higher RVO risk (odds ratio of  
38 RVO per 1 mmHg increase in IOP: 1.53; 95% confidence interval: 1.04 to 2.26; p-value = 0.03).  
39 Moreover, our MR mediation analysis suggested that 91.6% of the total effect of IOP on RVO  
40 risk was mediated through POAG. The primary results were consistent with estimates of  
41 pleiotropy-robust MR methods.

42 **Conclusion:** Our findings suggest that higher IOP increases the risk of RVO and that the  
43 majority of this effect is mediated through POAG.

44

45

## 46 **Introduction**

47 Retinal vein occlusion (RVO) is the second most common retinal vascular disease following  
48 diabetic retinopathy and an important cause of vision loss in individuals older than 80 years with  
49 a prevalence of 4.6% [1]. Risk factors for RVO are mainly related to atherosclerosis, but also  
50 conditions altering the rheologic properties in the retinal veins, such as hypercoagulability and  
51 vasculitis [2].

52 Glaucoma, an ocular disorder characterized by optic nerve damage and visual field loss, has  
53 been implicated in the pathogenesis of RVO [3]. Specifically, the association between RVO and  
54 primary open angle glaucoma (POAG) has been investigated in numerous studies, showing a  
55 significantly higher prevalence of RVO in patients with POAG compared to the general  
56 population [3,4]. Different pathogenic mechanisms have been proposed, implicating intraocular  
57 pressure which is a well-established and modifiable risk factor for glaucoma. On one hand,  
58 increased IOP has been hypothesized to collapse the retina vessel walls thus resulting in  
59 occlusion [5,6]. On the other hand, structural changes of the vessels at the glaucomatous optic  
60 discs might also make them more susceptible to thrombosis [7-10]. Whether RVO is caused by  
61 the effects of increased IOP independently from any glaucomatous optic disc abnormalities has  
62 not been determined.

63 Mendelian randomization (MR) serves as a robust methodology utilizing genetic variants  
64 derived from genome-wide association studies (GWAS) as instrumental variables to elucidate  
65 the causal relationship between modifiable exposures and disease outcomes [11]. A recent MR  
66 study has identified a positive association between POAG and RVO [12]. However, it was not  
67 assessed whether this observed effect is intrinsic to POAG itself or if it is a consequence of the  
68 elevated intraocular pressure that is mediated through POAG. In addressing this gap, we  
69 conducted a MR mediation analysis to discern the mediating role of POAG in the relationship

70 between IOP and RVO and sought to enhance our understanding of the nuanced interplay  
71 between these factors.

72

## 73 **Materials and Methods**

### 74 *Study design*

75 MR employs genetic variants as instrumental variables to investigate the impact of risk factors  
76 on disease susceptibility [11]. This method mitigates susceptibility to confounding and reverse  
77 causation, as these genetic variants are randomly assigned at conception, creating a quasi-  
78 randomized exposure allocation analogous to a randomized trial [11]. In our investigation, a two-  
79 sample MR was executed using summary statistics of single-nucleotide polymorphisms (SNPs)  
80 obtained from GWAS focusing on IOP [13] and RVO [14]. The aim was to evaluate the influence  
81 of IOP on the risk of RVO. Moreover, we tried to assess the proportion of the effect of IOP on  
82 RVO that is potentially mediated through POAG, by employing a two-step MR for mediation  
83 analysis [15]. The study protocol was not pre-registered and our research adhered to the  
84 STROBE-MR guidelines [16] and "Guidelines for performing Mendelian randomization  
85 investigations" [17].

### 86 *Data sources*

87 Summary data for corneal-compensated IOP were obtained from the UK Biobank (UKBB)  
88 cohort GWAS [13] (Supplementary Table 1). In particular, a subset comprising 97,653  
89 individuals within the UKBB underwent ophthalmic evaluations, encompassing the quantification  
90 of corneal-compensated IOP measured in millimeters of mercury (mmHg) through the  
91 application of a non-contact tonometer. The preference for corneal-compensated IOP as the  
92 selected exposure phenotype over regular IOP stems from its designed capability to  
93 accommodate corneal biomechanical properties. Moreover, this metric has been previously

94 employed in GWAS for IOP [18]. Summary data for RVO were obtained from the FinnGen  
95 consortium database's R9 release, involving a cohort of 775 documented RVO cases and  
96 376,502 controls [14]. The FinnGen GWAS participants were of European origin, and the  
97 identification of RVO cases adhered to diagnostic criteria established in either the International  
98 Classification of Diseases, Ninth Revision (ICD-9) or International Statistical Classification of  
99 Diseases, Tenth Revision (ICD-10) code. For the mediation MR analysis, GWAS summary  
100 statistics for POAG were also retrieved from a GWAS meta-analysis of 16,677 POAG cases and  
101 199,580 controls of European ancestry [19] (Supplementary Table 1). POAG cases were  
102 selected based on the ICD-9/ICD-10 criteria [19]. The genotyping, quality control, and  
103 imputation methods applied to the GWAS data used in our study have been detailed elsewhere  
104 [14,19,20].

#### 105 *Selection of genetic variants as instrumental variables*

106 We selected SNPs identified in the IOP GWAS that achieved genome-wide significance (P-  
107 value  $< 5 \times 10^{-8}$ ), following clumping for linkage disequilibrium (LD) at  $r^2 < 0.001$  over a 10mb  
108 window [17]. The MR-Steiger directionality test was employed to discern the directions of the  
109 causal relationship between IOP and RVO [21]. SNPs exhibiting a stronger correlation with the  
110 outcome than the exposure were systematically excluded, as were those demonstrating notable  
111 influence in the funnel plots and scatter plots. Ultimately, we identified 47 SNPs associated with  
112 IOP as instrumental variables. Furthermore, we quantified the proportion of variability in IOP  
113 that is explained by these 47 SNPs, through the summation of the coefficients of determination  
114 ( $R^2$ ) derived from the associations between the selected SNPs and IOP. Employing a similar  
115 approach, we chose 50 SNPs from the GWAS on POAG for utilization in our MR mediation  
116 analysis.

117

118 *Statistical analysis*

119 After the process of data harmonization based on HapMap3 [22], the removal of strand-  
120 ambiguous variants, and the alignment of association estimates, we proceeded to calculate  
121 Wald ratios. We calculated these ratios by dividing the logarithm of odds ratio per allele for each  
122 SNP identified in the GWAS for RVO by its respective estimate obtained from the IOP GWAS.  
123 Subsequently, the total effect of IOP on RVO risk was assessed through a multiplicative random  
124 effects inverse variance weighted (IVW) meta-analysis of the Wald ratios [23].

125 We implemented a univariable two-sample MR methodology, utilizing summary data extracted  
126 from GWAS of IOP and RVO. Our two-sample MR analysis was based on three key  
127 assumptions. Firstly, the imperative that the genetic variants selected should be associated with  
128 the targeted risk factor, a principle known as the "relevance" assumption [24]. We adhered to  
129 this assumption by choosing SNPs as instrumental variables that reached the threshold of  
130 genome-wide significance ( $P\text{-value} < 5 \times 10^{-8}$ ). Furthermore, we evaluated the strength of our  
131 instrumental variables by assessing the F-statistic of the selected SNPs, concurrently examining  
132 the proportion of variance in the exposure that they accounted for [25]. Secondly, the selected  
133 genetic instruments should not be correlated with factors that could potentially confound the  
134 relationship between the exposure and outcome, also known as the "exchangeability"  
135 assumption [24]. Thirdly, the "exclusion restriction" assumption [24], where the genetic  
136 instruments should not influence the outcome except through the risk factor of interest. While  
137 the "exchangeability" and "exclusion restriction" assumptions are inherently unverifiable, we  
138 executed sensitivity analyses to identify potential violations of these MR assumptions.

139 PhenoScanner [26] was employed to assess whether any of our selected genetic instruments  
140 were associated with phenotypes that could serve as potential confounders in our analysis. In  
141 instances where pleiotropic pathways were identified, we applied multivariable MR to adjust for  
142 these effects [27]. Moreover, we examined heterogeneity among our selected SNPs using the

143 Cochran Q heterogeneity test and  $I_{\text{ex}}^2$  [28] to detect pleiotropy, utilized several MR methods  
144 proposed to enhance robustness in instances where genetic variants exhibit pleiotropy [29] (MR  
145 Egger regression, penalized weighted median, IVW radial regression, and MR-Pleiotropy  
146 Residual Sum and Outlier (MR-PRESSO)) and performed a leave-one-out analysis to ascertain  
147 if the IVW estimate was influenced by a singular SNP.

148 To further explore the mediating effect of IOP on RVO through POAG, we conducted a two-step  
149 MR for mediation analysis, as outlined in previous literature [15]. This process involves the  
150 calculation of two distinct MR estimates: firstly, calculating the effect of IOP on POAG through a  
151 univariable MR model, and secondly, assessing the effect of POAG on RVO using a  
152 multivariable MR model that includes an adjustment for IOP. The IOP estimate on POAG  
153 multiplied with the adjusted POAG estimate on RVO provided the indirect effect of IOP on RVO,  
154 mediated through POAG. We also quantified the proportion of the total effect of IOP on RVO  
155 explained by the mediator (POAG) by dividing the calculated indirect effect of IOP on RVO by  
156 the total effect (adjusted direct and indirect effects of IOP on RVO). The delta method was  
157 employed to derive 95% confidence intervals (95%CI) for the indirect effect [30]. Furthermore,  
158 considering the inherent requirement for independence between the SNPs selected as  
159 instruments for the exposure (IOP) and mediator (POAG) in MR mediation analysis, we ensured  
160 that the selected SNPs from the IOP and POAG GWAS datasets were non-overlapping [15].  
161 This precautionary step was essential to uphold the validity and integrity of the MR for mediation  
162 analysis, preventing potential bias arising from SNP overlap.

163 We conducted all analyses with R version 4.2.1 [31] using the MVMR (0.3), TwoSampleMR  
164 (0.5.6), MendelianRandomization (0.5.1), MRPRESSO (1.0) and cause (1.2.0) packages.

165

166

167

## 168 **Results**

169 The 47 SNPs selected from the IOP GWAS (Supplementary Figure 1) accounted for 2.64% of  
170 the variability in IOP, with all SNPs displaying F-statistics of  $\geq 29.96$  (Supplementary Table 2).  
171 Employing the IVW method, genetically predicted IOP was positively associated with RVO risk  
172 (OR = 1.53 per 1mmHg increase in IOP; 95%CI = 1.04 to 2.26; P-value = 0.03) (Figure 2 and  
173 Supplementary Figure 2). Results from pleiotropy-robust MR methods aligned with the IVW  
174 analysis estimate (Figure 2). We found no associations of our selected SNPs with RVO risk  
175 factors apart from POAG (Supplementary Table 3) and, thus, we refrained from conducting  
176 multivariable MR to correct for potential correlated horizontal pleiotropy.

177 The Wald ratios for IOP with RVO did not exhibit heterogeneity (Supplementary Table 4) and  
178 the Cochran's Q heterogeneity test yielded a value of 37.89 (p-value = 0.797). Additionally, no  
179 evidence for directional pleiotropy was found, since the intercepts from the MR-Egger analyses  
180 did not deviate from zero (Supplementary Table 4). The leave-one-SNP-out analysis did not  
181 identify any SNPs exerting significant influence on the IVW estimate for the association between  
182 IOP and RVO risk (Supplementary Table 5).

183 An illustrative depiction of the MR mediation analysis can be seen in Figure 2. We found that  
184 91.6% of the total effect of IOP on RVO was mediated through POAG (Supplementary Table 6).

185

## 186 **Discussion**

187 In this MR mediation analysis, we utilized genetic data to disentangle the causal pathway  
188 between IOP and RVO, and to also explore the mediating role of POAG in this relationship. Our  
189 results support a positive causal effect of IOP on RVO which is mostly mediated through POAG.



190 Many studies have examined the relationship between glaucoma, specifically POAG, and risk  
191 for RVO [4]. Yin et al demonstrated in their meta-analysis that POAG is significantly associated  
192 with RVO risk (OR: 5.03; 95% CI: 3.97 to 6.37) [3]. Moreover, in their subgroup analysis, POAG  
193 and chronic open angle-glaucoma were also correlated with central RVO (OR: 13.30; 95% CI:  
194 3.34 to 53.20) and branch RVO (OR: 2.14; 95% CI: 1.09 to 4.20), but conclusions are guarded  
195 due to the small number of studies included in the meta-analyses. Similarly, Na et al.  
196 determined that the RVO incidence rate for the open-angle glaucoma patients was 528.95 per  
197 100,000 person-years (95% CI: 515.46 to 542.79), 3.27 times higher than in the general  
198 population [32]. Another Korean nationwide, population-based 11-year longitudinal study  
199 showed that patients with POAG were under higher risk for developing RVO (HR: 3.27, 95% CI:  
200 2.55-4.19) [33], while in the Beaver Dam Eye Study, no significant difference was found in the  
201 age-adjusted 5-year incidence of RVO between participants with and without POAG [34].

202 Different potential mechanisms have been proposed to interpret the association between POAG  
203 and RVO, and IOP has been shown to be a major contributing factor affecting retinal  
204 hemodynamics. It has been suggested that increased IOP may compress blood vessels,  
205 leading to proliferation of the vein intima and subsequently to the collapse of retinal vessel walls  
206 [5]. The effects of this mechanical compression are more pronounced at the level of the lamina  
207 cribrosa where the venous pressure is lowest. In older individuals with impaired retinal  
208 circulation and compromised autoregulatory vascular mechanisms, even a slight increase in  
209 IOP could be significant enough to decrease ocular blood flow, leading to venous slowing or  
210 stasis [6]. Luntz et al. strongly support an etiological relationship between increased IOP and  
211 central RVO having shown that the incidence of RVO in ocular hypertension is similar to that of  
212 POAG [35]. However, the Ocular Hypertension Treatment study, which included only  
213 participants with ocular hypertension, did not find a significant difference in RVO incidence  
214 between the observation and medication group [36].

215 The effect of IOP on retinal vessels might be further accentuated by anatomical characteristics  
216 of the glaucomatous optic nerve head. The posterior bowing of the lamina cribrosa present in  
217 glaucomatous optic discs confers less glial support to the retinal vessels thus making them  
218 more vulnerable to changes in IOP [8]. Also, higher cup-to-disc ratio has been correlated with  
219 the development of RVO, postulating that optic disc cupping induces structural abnormalities to  
220 the vessel at the disc, thus altogether making them susceptible to occlusion, venous stasis, and,  
221 consequently, to thrombosis, according to Virchow's triad [7,9,10]. On top of that, according to  
222 the vascular theory of glaucoma pathogenesis, patients with POAG have narrower retinal  
223 arteries and veins compared to normal individuals, predisposing them to greater vessel wall  
224 compression following a rise in IOP [37]. Moreover, it has been hypothesized that RVO and  
225 POAG could potentially arise from the same vascular abnormality given their shared vascular  
226 risk factors. Optic disc hemorrhages frequently encountered in POAG and RVO indicate small  
227 vein occlusions, raising the question of a common underlying pathway [38].

228 The key strength of this study is that it stands out as the first study to utilize the approach of MR  
229 mediation analysis to disentangle the complex causal pathway between IOP, POAG and RVO.  
230 Another strength of it lies in the consistency of association estimates obtained from pleiotropy-  
231 robust methods, aligning with the IVW estimate and indicating an absence of model violations.  
232 Nevertheless, certain limitations warrant consideration. Firstly, our investigation primarily  
233 focused on delineating the mediating role of POAG in the association between IOP and RVO,  
234 excluding exploration into other glaucoma subtypes such as primary angle-closure glaucoma.  
235 Secondly, our MR models assumed a linear relationship between the identified risk factors and  
236 the observed outcomes, whereas the true association among IOP, POAG, and RVO may  
237 manifest as non-linear. Thirdly, it is imperative to exercise caution when extrapolating the  
238 genetic associations derived from European populations to other ethnic groups due to potential  
239 population-specific variations. Fourthly, we did not assess the associations of IOP with the two

240 main subtypes of RVO, namely branch RVO and central RVO, since no GWAS datasets are  
241 available for these phenotypes.

242 In conclusion, our MR analyses infer an elevated risk of RVO associated with higher IOP. By  
243 utilizing MR mediation analysis, our findings additionally suggest that the majority of the effect of  
244 IOP on RVO risk is mediated through POAG. To advance our understanding of this intricate  
245 interplay, further investigations through population-based prospective studies, as well as  
246 experimental studies, are warranted to comprehensively explore the complex pathway involving  
247 IOP, POAG, and RVO.

248

249

250

251

252

253

254

255

256

257

258

259

260

261 **Author contributions**

262 KA, BSE and NM contributed to the study conception and design, drafted the manuscript and  
263 analyzed the data. All authors critically revised the manuscript for important intellectual content,  
264 provided administrative, technical, or material support and approved the final version.

265 **Data availability**

266 The summary statistics for the intraocular for the UKBB GWAS are available at  
267 <https://pan.ukbb.broadinstitute.org> (access date: 2023/10/12). The retinal vein occlusion  
268 summary statistics for the FinnGen GWAS are available at  
269 [https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results) (access date: 2023/10/12). The primary open-angle  
270 glaucoma summary statistics are available at <https://www.ebi.ac.uk/gwas/publications/33627673>  
271 (access date: 2023/10/12)

272 **Additional information**

273 Competing Interests: None declared

274 Acknowledgments: We want to acknowledge the participants and investigators of the FinnGen  
275 and UK Biobank studies.

276

277

278

279

280

281

282

283 **References**

- 284 1 Mitchell, P., Smith, W. & Chang, A. Prevalence and Associations of Retinal Vein  
285 Occlusion in Australia: The Blue Mountains Eye Study. *Arch. Ophthalmol.* **114**, 1243-  
286 1247, doi:10.1001/archopht.1996.01100140443012 (1996).
- 287 2 Kolar, P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of  
288 published clinical data. *J Ophthalmol* **2014**, 724780, doi:10.1155/2014/724780 (2014).
- 289 3 Yin, X., Li, J., Zhang, B. & Lu, P. Association of glaucoma with risk of retinal vein  
290 occlusion: A meta-analysis. *Acta Ophthalmol. (Copenh.)* **97**, 652-659,  
291 doi:10.1111/aos.14141 (2019).
- 292 4 Jabbehdari, S., Yazdanpanah, G., Cantor, L. B. & Hajrasouliha, A. R. A narrative review  
293 on the association of high intraocular pressure and glaucoma in patients with retinal vein  
294 occlusion. *Ann Transl Med* **10**, 1072, doi:10.21037/atm-22-2730 (2022).
- 295 5 Verhoeff FH. The effect of chronic glaucoma on the central retinal vessels. *Arch*  
296 *Ophthalmol.* 1913;42:145–52.
- 297 6 Frucht, J., Shapiro, A. & Merin, S. Intraocular pressure in retinal vein occlusion. *Br. J.*  
298 *Ophthalmol.* **68**, 26-28, doi:10.1136/bjo.68.1.26 (1984).
- 299 7 Beaumont, P. E. & Kang, H. K. Cup-to-disc ratio, intraocular pressure, and primary  
300 open-angle glaucoma in retinal venous occlusion<sup>1</sup>. *Ophthalmology* **109**,  
301 282-286, doi:10.1016/S0161-6420(01)00922-8 (2002).
- 302 8 Behrman, S. RETINAL VEIN OBSTRUCTION. *Br. J. Ophthalmol.* **46**, 336-342,  
303 doi:10.1136/bjo.46.6.336 (1962).
- 304 9 Dobree, J. H. Venous obstruction and neovascularization at the disc in chronic  
305 glaucoma. *Trans. Ophthalmol. Soc. U. K.* **77**, 229-237; discussion 237-228 (1957).

- 306 10 Rubinstein, K. & Jones, E. B. Retinal vein occlusion: long-term prospects: 10 years'  
307 follow-up of 143 patients. *Br. J. Ophthalmol.* **60**, 148-150, doi:10.1136/bjo.60.2.148  
308 (1976).
- 309 11 Sanderson, E. *et al.* Mendelian randomization. *Nature Reviews Methods Primers* **2**, 6,  
310 doi:10.1038/s43586-021-00092-5 (2022).
- 311 12 Zixun Wang, Zhiqing Li. Causal Association between Glaucoma and Risk of Retinal  
312 Vascular Occlusion: A Mendelian Randomization Study, 10 August 2023, PREPRINT  
313 (Version 1) available at Research Square, doi:10.21203/rs.3.rs-3223120/v1.
- 314 13 Pan-UKB team. <https://pan.ukbb.broadinstitute.org>. 2020.
- 315 14 Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated  
316 population. *Nature* **613**, 508-518, doi:10.1038/s41586-022-05473-8 (2023).
- 317 15 Carter, A. R. *et al.* Mendelian randomisation for mediation analysis: current methods and  
318 challenges for implementation. *Eur. J. Epidemiol.* **36**, 465-478, doi:10.1007/s10654-021-  
319 00757-1 (2021).
- 320 16 Skrivankova, V. W. *et al.* Strengthening the reporting of observational studies in  
321 epidemiology using mendelian randomisation (STROBE-MR): explanation and  
322 elaboration. *BMJ* **375**, n2233, doi:10.1136/bmj.n2233 (2021).
- 323 17 Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations:  
324 update for summer 2023 [version 3; peer review: 2 approved]. *Wellcome Open*  
325 *Research* **4**, doi:10.12688/wellcomeopenres.15555.3 (2023).
- 326 18 Simcoe, M. J., Khawaja, A. P., Hysi, P. G. & Hammond, C. J. Genome-wide association  
327 study of corneal biomechanical properties identifies over 200 loci providing insight into  
328 the genetic etiology of ocular diseases. *Hum. Mol. Genet.* **29**, 3154-3164,  
329 doi:10.1093/hmg/ddaa155 (2020).

- 330 19 Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma  
331 loci with consistent effect across ancestries. *Nature Communications* **12**, 1258,  
332 doi:10.1038/s41467-020-20851-4 (2021).
- 333 20 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.  
334 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 335 21 Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between  
336 imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081,  
337 doi:10.1371/journal.pgen.1007081 (2017).
- 338 22 Frazer, K. A. *et al.* A second generation human haplotype map of over 3.1 million SNPs.  
339 *Nature* **449**, 851-861, doi:10.1038/nature06258 (2007).
- 340 23 Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple  
341 instrumental variables in Mendelian randomization: comparison of allele score and  
342 summarized data methods. *Stat. Med.* **35**, 1880 - 1906 (2015).
- 343 24 Labrecque, J. & Swanson, S. A. Understanding the Assumptions Underlying  
344 Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related  
345 Tools. *Curr Epidemiol Rep* **5**, 214-220, doi:10.1007/s40471-018-0152-1 (2018).
- 346 25 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian  
347 randomization: using genes as instruments for making causal inferences in  
348 epidemiology. *Stat. Med.* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).
- 349 26 Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-  
350 phenotype associations. *Bioinformatics* **35**, 4851-4853,  
351 doi:10.1093/bioinformatics/btz469 (2019).
- 352 27 Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold Spring Harb.*  
353 *Perspect. Med.* **11**, doi:10.1101/cshperspect.a038984 (2021).

- 354 28 Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in  
355 Mendelian randomization studies. *Hum. Mol. Genet.* **27**, R195-R208,  
356 doi:10.1093/hmg/ddy163 (2018).
- 357 29 Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization methods  
358 using summary data. *Genet. Epidemiol.* **44**, 313-329, doi:10.1002/gepi.22295 (2020).
- 359 30 Ogasawara, H. Asymptotic standard errors of estimated standard errors in structural  
360 equation modelling. *Br. J. Math. Stat. Psychol.* **55**, 213-229,  
361 doi:10.1348/000711002760554552 (2002).
- 362 31 R Core Team (2022). R: A language and environment for statistical computing. R  
363 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- 364 32 Na, K. I., Jeoung, J. W., Kim, Y. K., Lee, W. J. & Park, K. H. Incidence of retinal vein  
365 occlusion in open-angle glaucoma: a nationwide, population-based study using the  
366 Korean Health Insurance Review and Assessment Database. *Clin. Experiment.*  
367 *Ophthalmol.* **46**, 637-644, doi:10.1111/ceo.13157 (2018).
- 368 33 Park, H. L., Jung, Y., Han, K., Lee, M. Y. & Park, C. K. Health care claims for primary  
369 open-angle glaucoma and retinal vein occlusion from an 11-year nationwide dataset.  
370 *Sci. Rep.* **7**, 8038, doi:10.1038/s41598-017-07890-6 (2017).
- 371 34 Klein, R., Klein, B. E., Moss, S. E. & Meuer, S. M. The epidemiology of retinal vein  
372 occlusion: the Beaver Dam Eye Study. *Trans. Am. Ophthalmol. Soc.* **98**, 133-141;  
373 discussion 141-133 (2000).
- 374 35 Luntz, M. H. & Schenker, H. I. Retinal vascular accidents in glaucoma and ocular  
375 hypertension. *Surv. Ophthalmol.* **25**, 163-167, doi:10.1016/0039-6257(80)90093-4  
376 (1980).
- 377 36 Barnett, E. M., Fantin, A., Wilson, B. S., Kass, M. A. & Gordon, M. O. The incidence of  
378 retinal vein occlusion in the ocular hypertension treatment study. *Ophthalmology* **117**,  
379 484-488, doi:10.1016/j.ophtha.2009.08.022 (2010).



- 380 37 Sonnsjö, B. & Krakau, C. E. Arguments for a vascular glaucoma etiology. *Acta*  
381 *Ophthalmol. (Copenh.)* **71**, 433-444, doi:10.1111/j.1755-3768.1993.tb04615.x (1993).  
382 38 Hayreh, S. S. Progress in the understanding of the vascular etiology of glaucoma. *Curr.*  
383 *Opin. Ophthalmol.* **5** (1994).

384

385

386

387

388

389

390

391

392

393

394

395

396


397

398

399

400 **Legends**

401 **Figure 1.** Mendelian randomization estimates for the effect of intraocular pressure on retinal  
402 vein occlusion. Estimates are reported as changes in odds of retinal vein occlusion per 1 mmHg  
403 increase in intraocular pressure.



404  
405 SNP, single nucleotide polymorphism; CI, confidence interval; MR-PRESSO, Mendelian  
406 randomization pleiotropy residual sum and outlier.

407

408

409


410

411

412

413

414 **Figure 2.** Directed acyclic graphs of the mediation analysis with Mendelian randomization.



415

416 The indirect effect of intraocular pressure (IOP) on retinal vein occlusion (RVO) can be  
417 calculated by multiplying  $\alpha$  times  $\beta$ , where  $\alpha$  is the effect of IOP on primary open-angle  
418 glaucoma (POAG), and  $\beta$  the effect of POAG on RVO. The proportion mediated can be  
419 estimated by dividing the indirect effect by the total effect of IOP on RVO. All estimates are  
420 shown as the difference in the logarithm of odds of the outcome, per 1 unit increase of the

421 exposure (continuous variables: IOP) or between the two exposure groups (binary variables:  
422 POAG).

423